Cargando…
Potentials to alleviate coagulopathy and enhance microglial function of beta (β)- glucans, making them worth a clinical study for COVID-19's neurological sequalae
Autores principales: | Raghavan, Kadalraja, Kandaswamy, Ramesh Shankar, Ikewaki, Nobunao, Iwasaki, Masaru, Abraham, Samuel J.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219294/ https://www.ncbi.nlm.nih.gov/pubmed/34186495 http://dx.doi.org/10.1016/j.jns.2021.117554 |
Ejemplares similares
-
Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2022) -
Benefits of Gut Microbiota Reconstitution by Beta 1,3–1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases
por: Raghavan, Kadalraja, et al.
Publicado: (2023) -
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2022) -
Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2023) -
Qualitative Evaluation of α-Synuclein: A Critical Step in Unravelling the Complexities of Autism Spectrum Disorder
por: Preethy, Senthilkumar, et al.
Publicado: (2022)